

Sir:

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of:	
Norbert HEIMBURGER et al.) Group Art Unit: To be assigned
Application No.: 10/568,687	Examiner: To be assigned
Filed: February 17, 2006	
For: C1-INH AS A DRUG FOR TREATING VIRUSES PATHOGENIC TO HUMANS)))
Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450	

INFORMATION DISCLOSURE STATEMENT UNDER 37 C.F.R. § 1.97(b)

Pursuant to 37 C.F.R. §§ 1.56 and 1.97(b), Applicants bring to the attention of the Examiner the documents on the attached listing. This Information Disclosure Statement is being filed before the mailing date of a first Office Action.

Copies of the listed foreign and non-patent literature documents are attached.

Copies of the U.S. patent publications are not enclosed. Applicants respectfully request that the Examiner consider the listed documents and indicate that they were considered by making appropriate notations on the attached form.

This submission does not represent that a search has been made or that no better art exists and does not constitute an admission that each or all of the listed documents are material or constitute "prior art." If the Examiner applies any of the documents as prior art against any claim in the application and Applicants determine

that the cited documents do not constitute "prior art" under United States law,

Applicants reserve the right to present to the Office the relevant facts and law regarding
the appropriate status of such documents.

Applicants further reserve the right to take appropriate action to establish the patentability of the disclosed invention over the listed documents, should one or more of the documents be applied against the claims of the present application.

If there is any fee due in connection with the filing of this Statement, please charge the fee to Deposit Account No. 06-0916.

Respectfully submitted,

FINNEGAN, HENDERSON, FARABOW, GARRETT & DUNNER, L.L.P.

Dated: April 19, 2006

By: / Maryanu / .

Reg. No. 52,138

						010
IDS Form PTO/SB/08: Substitute for form 1449A/PTO		Complete if Known				
				Application Number	10/568,687	APR ,
INFORMATION DISCLOSURE			Filing Date	February 17, 2006	9 200s	
STATEMENT BY APPLICANT		First Named Inventor	Norbert HEIMBURGER			
(Use as many sheets as necessary)			Art Unit	To be assigned	Plan die	
			Examiner Name	To be assigned	THARK OF	
Sheet	1	of	1	Attorney Docket Number	6478 1505-00	

U.S. PATENTS AND PUBLISHED U.S. PATENT APPLICATIONS						
Examiner Cite Initials No.	Cite		Issue or Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where	
	No.'	Number-Kind Code ² (if known)			Relevant Passages or Relevant Figures Appear	
		US- 6,242,239	06-05-2001	Gröner		
		US-				
		US-				
		US-				
		US-				
		US-	1			

Note: Submission of copies of U.S. Patents and published U.S. Patent Applications is not required.

	FOREIGN PATENT DOCUMENTS						
Examiner Initials	Cite No. ¹	Foreign Patent Document Country Code ³ Number ⁴ Kind Code ⁵ (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	Translation or Equivalent ⁶	
		EP 0 969 017 A1	06-18-1999	Centeon Pharma GmbH		CA 2276564	

		NON PATENT LITERATURE DOCUMENTS	
Examiner Initials	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	Translation ⁶
		Drouet, C. et al., "Hepatitis C Virus NS3 Serine Protease Interacts with the Serpin C1 Inhibitor" Febs Lett. 458:415-18 (1999).	
		Kirschfink, M. et al., "C1-Inhibitor: An Anti-Inflammatory Reagent with Therapeutic Potential" Exp. Opin. Pharmacotherapy 2:1073-83 (2001).	
		International Search Report dated January 21, 2005 for application PCT/EP2004/009085.	

Examiner	Date	
Signature	Considered	

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.